‹³ˆõî•ñ
Ž–¼ r–ì@‘×
ƒtƒŠƒKƒi ƒAƒ‰ƒm@ƒ„ƒXƒV
E–¼ ‹³Žö
ŠwˆÊ –òŠw”ŽŽm
Œ¤‹†Žº •ªŽq‰æ‘œ–ò•iŠw
“d˜b”ԍ† 043-226-2896
ƒ[ƒ‹ƒAƒhƒŒƒX arano—chiba-u.jp@i—‚Í‘SŠp•\‹Lj
’S“–u‹` •¨—‰»ŠwúK
•¨—‰»ŠwúM
•ªŽqƒCƒ[ƒWƒ“ƒO–òÜŠw
—Տ°ŒŸ¸Ef’f–òŠw
–òÜŠwúL
‰q¶E•úŽË–òŠwŽÀKB
ŽÐ‰ï‚Ì’†‚Ì‚­‚·‚èi••Õ‰È–ځj
ê–啪–ì •úŽË«–ò•i‰»Šw
•ªŽqƒCƒ[ƒWƒ“ƒO–òÜŠw
Œ¤‹†ƒe[ƒ} •ªŽqƒCƒ[ƒWƒ“ƒOƒvƒ[ƒu‚¨‚æ‚уAƒCƒ\ƒg[ƒvŽ¡—ÖòÜ‚ÌŠJ”­
Žå‚ÈŒ¤‹†‹ÆÑ Guerra Gomez FL, Uehara T, Rokugawa T, Higaki Y, Suzuki H, Hanaoka H, Akizawa H, Arano Y.: Synthesis and evaluation of diastereoisomers of 1,4,7-triazacyclononane-1,4,7-tris-(glutaric acid) (NOTGA) for multimeric radiopharmaceuticals of gallium. Bioconjugate Chem. 23, 2229-2238, 2012.

Thipyapong, K., Uehara, T., Tooyama, Y., Braband, R., Alberto, R., Arano Y.: Insight into technetium amidoxime complex: Oxo technetium(V) complex of N-substituted benzamidoxime as new basic structure for molecular imaging. Inorg. Chem. 50, 992-998 (2011)

Miyamoto, R., Akizawa, H., Nishikawa, T., Uehara, T., Azuma, Y., Nakase, I., Futaki, S., Hanaoka, H., Iida, Y., Endo, K., Arano, Y. Enhanced target specific accumulation of radiolabeled antibodies by conjugating arginine-rich peptides as anchoring molecules. Bioconjugate Chem. 21, 2031-2037, (2010)

Suzuki, K., Shimmura, N., Thipyapong, K., Uehara, T., Akizawa, H., Arano, Y. Assessment of macrocyclic triamine ligands as syntons for organometallic 99mTc radiopharmaceuticals. Inorg. Chem. 47, 2593-2600 (2008)

Akizawa, H., Uehara, T., Arano, Y. Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins. Adv. Drug Deliv. Rev. 60, 1319-1328 (2008)
Š‘®Šw‰ï “ú–{–òŠw‰ï
“ú–{ŠjˆãŠw‰ï
“ú–{DDSŠw‰ï
ƒˆƒE‘fŠw‰ï
•Ä‘ŠjˆãŠw‰ï
ŠwŠO‚Å‚Ì‹³ˆçEŒ¤‹†Šˆ“® “ú–{ŠjˆãŠw‰ï—Ž–i2007-2011jA•úŽË«ˆã–ò•iŽæ‚舵‚¢ƒKƒCƒhƒ‰ƒCƒ“ˆÏˆõ’·
“ú–{ƒAƒCƒ\ƒg[ƒv‹¦‰ï (1) ˆãŠwE–òŠw•”‰ïê–åˆÏˆõiŠé‰æê–åˆÏˆõ‰ïA•úŽË«ˆã–ò•i‚̗Տ°•]‰¿ê–åˆÏˆõ‰ïA•úŽË«ˆã–ò•iˆÀ‘S«ê–åˆÏˆõ‰ïA•úŽË«ˆã–ò•iê–åˆÏˆõ‰ïj, (2) 99Mo‘ŽY‰»ŒŸ“¢ˆÏˆõ‰ïˆÏˆõ’·
ƒˆƒE‘fŠw‰ï•]‹cˆõA‹à‘®‚ªŠÖ—^‚·‚鐶‘ÌŠÖ˜A”½‰žƒVƒ“ƒ|ƒWƒEƒ€•]‹cˆõ
NEDO•]‰¿ŽÒAJST •]‰¿ŽÒ
•¶‰ÈÈ‰ÈŠw‹Zp­ôŒ¤‹†Š‰ÈŠw‹Zp“®ŒüƒZƒ“ƒ^[ê–å’²¸ˆõ
‰ªŽR‘åŠw•ªŽqƒCƒ[ƒWƒ“ƒO‚“xê–ålÞˆç¬Ž–‹ÆŠw•”•]‰¿ˆõi2011-j
‹à‘ò‘åŠwŠwÛŽÀŒ±ƒZƒ“ƒ^[@ŠO•”•]‰¿ˆÏˆõi2009jAŠò•Œ–ò‰È‘åŠwŠO•”•]‰¿ˆÏˆõi2012j
“Œ–k‘åŠwƒTƒCƒNƒƒgƒƒ“ERIƒZƒ“ƒ^[ŠO•”•]‰¿ˆõi2013j